U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H32ClN3O8S
Molecular Weight 630.108
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELIVAPTAN

SMILES

COC1=CC=C(C(OC)=C1)S(=O)(=O)N2C(=O)[C@@](N3C[C@H](O)C[C@H]3C(=O)N(C)C)(C4=CC(Cl)=CC=C24)C5=C(OC)C=CC=C5

InChI

InChIKey=NJXZWIIMWNEOGJ-WEWKHQNJSA-N
InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1

HIDE SMILES / InChI

Molecular Formula C30H32ClN3O8S
Molecular Weight 630.108
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Nelivaptan is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. It showed promise in preclinical animal models and advanced to phase II clinical trials for the treatment of anxiety and depression; however, in 2008, Sanofi-Aventis announced that further development of this drug had been halted.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.54 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
Nelivaptan was prepared as a solution in physiological saline containing 0.1% Tween80 or 5% DMSO and 5% Cremphor EL. Drugs were delivered in a constant volume of 2 mL/kg (rat) and containing 3, 10 or 20 mg/kg of Nelivaptan. Rats were evaluated for stress response in a Punished Drinking Test, in an elevated Plus-Maze and a forced swim test. Doses of 3 and 10 mg/kg significantly increased punished drinking. A dose of 10 and 30 mg/kg increased the boldness of rats in the elevated maze test. In the forced swim test, nelivaptan had a significant effect on the immobility time at doses of 10 mg/kg and up.
Route of Administration: Oral
In Vitro Use Guide
CHO-dhFr- cells were transfected with an expression vector derived from plasmid 7055 containing the cDNA encoding the human V1b receptor. Stabley transfected cells were grown in 10 mM HEPES, pH 7.4, minimal essential medium supplemented with 5% fetal calf serum and 8 g/L sodium bicarbonate and 300 micro-G.mL geneticin at 37 deg-C and under a 5% CO2 atmosphere. Binding assays on membranes of CHO cells transfected with the human or rat V1b receptor were performed in an incubation medium containing 50 mM Tris-HCl, pH 7.4; 3 mM MgSO4; 0.1% BSA; 0.1% bacitracin; [3H]AVP; and increasing amounts of Nelivaptan (0.9, 1.8, 3.7, 7.5, and 15 nM). Nonspecific binding was determined in the presence of 1 μM unlabeled AVP. Nelivaptan dose-dependently antagonized [3H]AVP binding to various membrane preparations from CHO cell lines transfected with the rat and human V1b receptors. Nelivaptan had an affinity for human V1b receptors close to that of the natural hormone, AVP (Ki values of 1.54 ± 0.82 and 0.80 ± 0.25 nM, respectively)
Substance Class Chemical
Record UNII
3TY57MQ4OA
Record Status Validated (UNII)
Record Version